Cellectar's CLR 131 reduces tumor burden by 94% in patient with Waldenström's macroglobulinemia

Cellectar Biosciences Inc. (NASDAQ:CLRB) said a patient with advanced Waldenström's macroglobulinemia receiving CLR 131 in a Phase II trial achieved a 94%

Read the full 228 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE